```html

Non‑rheumatic Aortic Valve Disease: A Patient‑Focused Guide

Overview

Non‑rheumatic aortic valve disease (NRAVD) refers to structural or functional problems of the aortic valve that are not caused by rheumatic fever. The two most common forms are:

• Aortic stenosis (AS) – narrowing of the valve opening, which restricts blood flow from the left ventricle into the aorta.
• Aortic regurgitation (AR) – leakage of blood back into the left ventricle because the valve does not close tightly.

Both conditions can coexist (mixed disease). NRAVD typically affects adults, especially older adults, but younger patients may be affected when congenital anomalies, genetic disorders, or certain lifestyle factors are present.

Who It Affects

• Age: Incidence rises sharply after age 65. About 3‑4% of people over 75 have moderate‑to‑severe AS.
• Sex: Severe AS is slightly more common in men; severe AR is similarly distributed.
• Geography: In Western countries, degenerative calcific disease is the leading cause; in parts of Asia and Africa, bicuspid aortic valve (a congenital anomaly) accounts for a larger share.

Prevalence

Combined estimates suggest that >2% of adults >75 years have clinically significant aortic valve disease. In the United States, >2 million people live with aortic stenosis, and >500,000 are projected to require valve replacement within the next decade (CDC, 2022).

Symptoms

Early disease is often silent. Symptoms usually appear once the valve obstruction or leak becomes severe enough to affect cardiac output.

Aortic Stenosis

• Exertional dyspnea – shortness of breath with activity due to reduced forward flow.
• Angina (chest pain) – caused by increased myocardial oxygen demand.
• Syncope or presyncope – fainting episodes, especially during exertion.
• Fatigue – generalized weakness even with mild activity.
• Palpitations – irregular heartbeats may develop from atrial enlargement.

Aortic Regurgitation

• Rapid, bounding pulse – “water‑hammer” pulse felt in the carotid.
• Exertional dyspnea – especially when lying flat (orthopnea).
• Chest discomfort – often less classic than in AS.
• Palpitations – due to atrial fibrillation.
• Reduced exercise tolerance – feeling winded after short walks.

Mixed Disease

Patients may experience a combination of the above signs, making the clinical picture more complex.

Causes and Risk Factors

NRAVD is heterogeneous. The underlying mechanisms differ between stenosis and regurgitation.

Degenerative (Calcific) Aortic Stenosis

• Age‑related calcification – calcium deposits slowly stiffen the leaflets.
• Hyperlipidemia – LDL cholesterol contributes to atherosclerotic‑like changes.
• Hypertension – chronic pressure load accelerates wear.
• Smoking – oxidative stress promotes calcification.

Bicuspid Aortic Valve (BAV)

The most common congenital valve abnormality (1‑2% of the population). A valve with two leaflets is prone to early calcification, stenosis, and regurgitation, often presenting in the 4th–5th decade.

Connective‑Tissue Disorders

• Marfan syndrome, Loeys‑Dietz, and Ehlers‑Danlos – weaken the aortic root, leading to annular dilation and AR.

Infective Endocarditis

Although an infectious cause, it is classified separately from rheumatic fever. Damage from bacteria can perforate leaflets, causing acute regurgitation.

Other Acquired Causes of Regurgitation

• Radiation therapy to the chest (e.g., for lymphoma) – fibrotic changes.
• Aortic root dilation from uncontrolled hypertension or aortic aneurysm.
• Trauma – blunt chest injury can tear the valve.

Risk Factors Summary

Factor	Impact
Age > 65 yrs	Strongest predictor for calcific AS
Bicuspid valve	10‑20× higher risk of early disease
High LDL cholesterol	Promotes leaflet calcification
Hypertension	Accelerates both AS and AR
Smoking	Increases oxidative damage
Family history of valve disease	Genetic predisposition

Diagnosis

Because early disease is often silent, diagnosis usually follows a routine exam, symptom evaluation, or an incidental finding on imaging.

Physical Examination

• Systolic ejection murmur – harsh, radiates to the carotids in AS.
• Diastolic decrescendo murmur – best heard along the left sternal border in AR.
• Palpable “thrill” or bounding pulses.

Imaging & Tests

1. Transthoracic echocardiography (TTE) – first‑line. Measures valve area, mean gradient, regurgitant volume, and left‑ventricular size/function. Sensitivity >90% for moderate‑to‑severe disease.
2. Transesophageal echocardiography (TEE) – provides superior resolution of valve morphology, useful for surgical planning.
3. Cardiac CT (CT‑angiography) – quantifies calcium score (Agatston) and evaluates aortic root anatomy; valuable when echo windows are poor.
4. Cardiac MRI – precise assessment of ventricular volumes and regurgitant fraction, especially in AR.
5. Electrocardiogram (ECG) – may show left‑ventricular hypertrophy (LVH) in AS or atrial fibrillation in AR.
6. Exercise stress testing – determines functional capacity and symptom provocation when the diagnosis is uncertain.
7. Cardiac catheterization – reserved for cases where coronary artery disease must be ruled out before valve surgery.

Severity Criteria (Guidelines from the American College of Cardiology/AHA, 2023)

Parameter	Aortic Stenosis	Aortic Regurgitation
Valve area (cm²)	Severe ≤1.0	–
Mean gradient (mm Hg)	Severe ≥40	–
Peak velocity (m/s)	Severe ≥4.0	–
Regurgitant volume (ml/beat)	–	Severe ≥60
Effective regurgitant orifice (cm²)	–	Severe ≥0.30
Left‑ventricular ejection fraction (LVEF)	↓ ≥ 50% indicates symptomatic severe AS	↓ ≤ 50% signifies severe AR

Treatment Options

Treatment is individualized based on severity, symptoms, ventricular function, and patient comorbidities.

Medical Management

• Blood pressure control – ACE inhibitors, ARBs, or calcium‑channel blockers to reduce afterload in AR.
• Statin therapy – may slow progression of calcific AS, although data are mixed (NIH, 2021).
• Diuretics – relieve pulmonary congestion in advanced AR.
• Anticoagulation – indicated if atrial fibrillation develops.
• Activity modification – avoid strenuous exertion in severe AS.

Medical therapy alone does not halt disease progression; it primarily alleviates symptoms and prepares patients for possible intervention.

Procedural Interventions

1. Surgical Aortic Valve Replacement (SAVR)

Traditional open‑heart surgery with a mechanical or bioprosthetic valve. Indicated for:

• Severe symptomatic AS or AR.
• Left‑ventricular ejection fraction <50%.
• Younger patients (<65 yrs) who can tolerate lifelong anticoagulation (mechanical valves).

2. Transcatheter Aortic Valve Replacement (TAVR)

Minimally invasive catheter‑based implantation of a bioprosthetic valve. Now approved for:

• Patients ≥65 yrs with severe AS irrespective of surgical risk.
• Selected low‑risk patients (evidence from PARTNER 3 and Evolut Low Risk trials).

3. Aortic Valve Repair (for AR)

In select cases (especially with a bicuspid valve and normal root size) the valve can be repaired rather than replaced, preserving native tissue.

4. Aortic Root/Ascending Aorta Surgery

When annular dilation or aneurysm coexists, combined valve‑and‑root replacement (Bentall procedure) is performed.

Lifestyle and Supportive Measures

• Adopt a heart‑healthy diet (Mediterranean style, low sodium, low saturated fat).
• Engage in moderate aerobic activity (e.g., brisk walking 30 min most days) unless restricted by physician.
• Maintain optimal weight (BMI 18.5‑24.9) to lessen cardiac workload.
• Quit smoking and limit alcohol intake.
• Stay up‑to‑date on vaccinations (influenza, pneumococcal, COVID‑19) to avoid respiratory infections that strain the heart.

Living with Non‑rheumatic Aortic Valve Disease

Self‑Monitoring

• Track exercise tolerance: note any new shortness of breath, chest pain, or dizziness.
• Monitor pulse quality; a sudden change from a bounding to a weak pulse can signal worsening AR.
• Weigh yourself daily; a rapid weight gain (>2 lb in 24 h) may indicate fluid retention.

Medication Adherence

Set alarms or use a pill‑box; communicate any side effects to your clinician promptly.

Regular Follow‑up

Guidelines recommend:

• Annual echocardiogram for mild‑to‑moderate disease.
• Every 6‑12 months if the valve area is 1.0‑1.5 cm² or if LVEF is declining.

Psychosocial Support

Join patient support groups (e.g., American Heart Association “Valve Disease” community) and consider counseling if anxiety about surgery is high.

Prevention

While you cannot change age or genetics, you can modify many risk factors.

• Control cholesterol – diet, exercise, and statins when indicated.
• Manage hypertension – target < 130/80 mm Hg (ACC/AHA 2023).
• Quit smoking – seek nicotine‑replacement therapy or counseling.
• Regular dental care – reduces bacteremia risk that can precipitate endocarditis.
• Prophylactic antibiotics before certain dental or invasive procedures if you have a prosthetic valve or prior endocarditis (per AHA guidelines).

Complications

If left untreated, NRAVD can lead to serious, life‑threatening problems:

• Heart failure – due to pressure overload (AS) or volume overload (AR).
• Arrhythmias – atrial fibrillation from atrial enlargement, ventricular tachycardia in advanced disease.
• Sudden cardiac death – especially in severe AS with syncope.
• Infective endocarditis – damaged valves are a nidus for infection.
• Aortic aneurysm or dissection – especially when the root is dilated in AR.
• Thromboembolic events – prosthetic valves and atrial fibrillation increase stroke risk.

When to Seek Emergency Care

References

• Mayo Clinic. “Aortic Stenosis.” https://www.mayoclinic.org. Accessed June 2026.
• American Heart Association. “Valvular Heart Disease.” https://www.heart.org. 2023 guideline update.
• Centers for Disease Control and Prevention. “Heart Disease and Stroke Statistics.” 2022.
• National Institutes of Health. “Statins and Calcific Aortic Valve Disease.” JAMA Cardiology, 2021.
• Society of Thoracic Surgeons and Cardiovascular and Interventional Radiological Society of Europe. “2023 ACC/AHA Guideline for the Management of Valvular Heart Disease.”
• Cleveland Clinic. “Bicuspid Aortic Valve.” https://my.clevelandclinic.org. 2024.
• World Health Organization. “Non‑communicable Diseases Fact Sheet.” 2024.

```